Health Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic… James Pereira Sep 12, 2022 SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company… Read More...
Health A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline |… James Pereira Jun 9, 2021 Los Angeles, June 08, 2021 (GLOBE NEWSWIRE) -- A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic… Read More...
